News

Fierce Pharma3d
FDA delays Blenrep decision, putting GSK's multiple myeloma comeback dreams on ice
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...
BioSpace3d
GSK’s Comeback for Blenrep on Pause as FDA Delays Decision
The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.
CURE9d
FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma
The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...